免疫监视
医学
免疫疗法
肿瘤微环境
免疫系统
临床试验
癌症
癌症免疫疗法
Toll样受体
癌症研究
放射治疗
免疫学
内科学
先天免疫系统
作者
Julie Le Naour,Guido Kroemer
出处
期刊:OncoImmunology
[Informa]
日期:2023-02-17
卷期号:12 (1)
被引量:3
标识
DOI:10.1080/2162402x.2023.2180237
摘要
Accumulating evidence indicates that Toll-like receptor (TLR) agonists proficiently (re)instore cancer immunosurveillance as immunological adjuvants. So far, three TLR agonists have been approved by regulatory agencies for use in oncological applications. Additionally, these immunotherapeutics have been extensively investigated over the past few years. Multiple clinical trials are currently evaluating the combination of TLR agonists with chemotherapy, radiotherapy, or different immunotherapies. Moreover, antibodies targeting tumor-enriched surface proteins that have been conjugated to TLR agonists are being developed to stimulate anticancer immune responses specifically within the tumor microenvironment. Solid preclinical and translational results support the favorable immune-activating effects of TLR agonists. Here, we summarize recent preclinical and clinical advances in the development of TLR agonists for anticancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI